Oragenics (NYSE:OGEN) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a research note issued to investors on Tuesday. The brokerage set a “sell” rating on the stock.

Oragenics Trading Down 0.8 %

Shares of NYSE:OGEN opened at $1.22 on Tuesday. The stock has a 50-day simple moving average of $2.15. Oragenics has a 12-month low of $1.15 and a 12-month high of $7.74. The firm has a market cap of $5.47 million, a price-to-earnings ratio of -0.13 and a beta of 0.31.

Oragenics (NYSE:OGEN) last issued its quarterly earnings results on Friday, March 29th. The company reported ($5.48) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Oragenics

A number of large investors have recently modified their holdings of the company. State Street Corp raised its holdings in shares of Oragenics by 8.1% in the 1st quarter. State Street Corp now owns 495,563 shares of the company’s stock worth $171,000 after purchasing an additional 37,338 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Oragenics by 24.4% in the 4th quarter. Renaissance Technologies LLC now owns 288,398 shares of the company’s stock worth $30,000 after purchasing an additional 56,498 shares during the period. Finally, Millennium Management LLC raised its holdings in shares of Oragenics by 591.6% in the 2nd quarter. Millennium Management LLC now owns 128,733 shares of the company’s stock worth $45,000 after purchasing an additional 110,119 shares during the period. 18.71% of the stock is currently owned by hedge funds and other institutional investors.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.